At a glance
The history of Privigen, the first proline-stabilised 10% liquid IVIG, and five research papers that extended it: 36-month room-temperature stability, the PRIMA CIDP trial, the PATH restabilisation data, a hospital audit showing a 90% cut in haemolytic anaemia, and pandemic-era findings on batch variation.
Privigen is an intravenous immunoglobulin — IVIG, which is the short way of saying antibodies pooled from the plasma of thousands of donors and dripped into a vein — and it has one defining quirk. It does not want to live in your fridge.
That quirk explains most of the drug's history. When the US Food and Drug Administration licensed it on 26 July 2007, Privigen was the first 10% liquid IVIG stabilised with proline, an amino acid, at a weakly acidic pH of 4.8. The chemistry solved a logistics problem. A product that can sit at room temperature and go straight into a line doesn't need a pharmacist with a timer, a shaker and a spare twenty minutes.
Nobody tells you how much of hospital pharmacy is spent on that timer. My first sight of IVIG as a junior was a vial-and-spike ritual that ended in a bag of something resembling weak apple juice. Ready-to-use 10% liquids quietly deleted the ritual, and almost nobody outside pharmacy noticed.
What follows is the backstory, plus five papers that pushed the product further: a stability study that got the refrigerator out of the supply chain, a small single-arm trial that won it a neurology licence, the trial that showed a different route of delivery holds, a manufacturing fix validated against real hospital records, and a pandemic-era paper with an awkward finding about batch-to-batch variation.
What is actually in the vial
Start with the raw material, because it explains the warnings. IVIG is a pooled blood product: plasma from thousands of donations, fractionated and purified into a concentrate of polyclonal immunoglobulin G (IgG, the workhorse antibody class). Privigen's process uses octanoic acid fractionation followed by chromatography, includes three dedicated virus inactivation and removal steps, and formulates the result with 250 millimolar L-proline at pH 4.8. The IgG fraction runs at 98% purity or better, and the product contains no sucrose — which matters because sucrose-containing IGIV products carry a higher rate of kidney injury in the label's own boxed warning.
Proline is what makes room-temperature storage possible, and it also writes one of the contraindications: people with hyperprolinaemia, a rare disorder of proline metabolism, can't receive the drug. There's a kitchen-table version of the chemistry. Proteins in a crowded solution want to clump, and clumping is the last thing you want in something you're infusing. Proline keeps the crowd polite.
Dosing is not delicate. In chronic immune thrombocytopenic purpura (ITP, a condition where platelets fall low enough to risk bleeding), the regimen is 1 g/kg on two consecutive days. In chronic inflammatory demyelinating polyneuropathy (CIDP, an autoimmune attack on the myelin sheath of peripheral nerves), it's a loading dose of 2 g/kg split over two to five days, then 1 g/kg every three weeks, starting at an infusion rate of 0.5 mg/kg per minute and climbing to 8 mg/kg per minute as tolerated.
Photo by Brett Jordan on Unsplash
How a plasma product picked up a neurology licence
The early years were about replacement therapy — topping up antibodies for people whose immune systems don't make enough — and then about immunomodulation, where the same antibodies are used for what they do to an overactive immune system rather than what they fight.
| Date | Milestone |
|---|---|
| 26 July 2007 | FDA licenses Privigen (BLA 125201, CSL Behring AG) for primary immunodeficiency and chronic ITP — the first proline-stabilised 10% liquid IVIG |
| 7 February 2008 | US launch |
| 2008 | Swissmedic approval in April, followed by marketing authorisation across the European Union and European Economic Area |
| April 2010 | FDA extends room-temperature shelf life from 24 to 36 months |
| February 2013 | FDA approves a 40 g (400 mL) vial for high-volume dosing |
| March 2013 | European Commission adds CIDP to the label |
| 2016–2017 | Anti-A/anti-B immunoaffinity chromatography step (marketed as Ig IsoLo) rolled out globally |
| September 2017 | FDA approves Privigen for adults with CIDP, to improve neuromuscular disability and impairment |
The European label reaches wider than the American one, covering Guillain-Barré syndrome, Kawasaki disease, multifocal motor neuropathy and use after allogeneic bone marrow transplant. The US CIDP indication comes with a limitation of use written into the label: maintenance therapy has not been studied beyond six months, and not every responder needs indefinite treatment.
Five papers that took it further
The order below is roughly chronological, which is also roughly the order in which each result changed what clinicians could do on a Monday morning.
The stability study that removed the fridge
A 2009 paper in Vox Sanguinis by M. Cramer and colleagues at CSL Behring put the formulation through 36 months of controlled storage at 25°C. Almost nothing moved. Purity stayed at 98% or above, no relevant quantities of aggregated IgG formed, the monomer-to-dimer ratio drifted slightly toward equilibrium, and both reference antibody content and Fc function — the part of the antibody that recruits the immune system — held. The solution met European Pharmacopoeia appearance specifications throughout, with a single exception. Dimer content stayed at or below 12%, which is the point of proline: it restricts idiotype/anti-idiotype dimer formation better than glycine does.
Those data became a regulatory decision. In April 2010 the FDA extended the product's room-temperature shelf life from 24 to 36 months, the first 10% liquid IVIG to get there. Epidemiologically this is small. Operationally it's enormous: long shelf life means stock can sit in a clinic in a country where cold chain is expensive, and a bag can be started at 2 a.m. without anyone hunting for a fridge log. Read the full stability study in Vox Sanguinis.
PRIMA: the trial that won the neurology label
PRIMA — Privigen Impact on Mobility and Autonomy — was a prospective, multicentre, single-arm, open-label Phase III study in 28 adults with CIDP, 13 of them already on IVIG and 15 treatment-naive. Everyone got an induction dose of 2 g/kg and up to seven maintenance doses of 1 g/kg at three-week intervals. The primary endpoint was a drop of at least one point on the adjusted INCAT (Inflammatory Neuropathy Cause and Treatment) disability scale, and the pre-set bar for success was a 35% responder rate.
The result was 60.7%, with a 95% confidence interval of 42.4% to 76.4%. Pre-treated patients responded at 76.9%; treatment-naive patients at 46.7%. Median INCAT score improved from 3.5 to 2.5, maximum grip strength rose from 66.7 to 80.9 kPa, and the Medical Research Council sum score went from 67.0 to 75.5. Of 108 adverse events — 0.417 per infusion — 88% were mild or moderate. Two serious events of haemolysis resolved after treatment stopped. The European Commission added CIDP on the strength of it in March 2013; the FDA followed in September 2017, after the PATH data arrived. The paper is in the Journal of the Peripheral Nervous System.
PATH: where Privigen was the run-in, not the question
PATH (Polyneuropathy and Treatment with Hizentra) asked whether subcutaneous immunoglobulin could hold CIDP patients in remission. It randomised 172 people across 69 neuromuscular centres in North America, Europe, Israel, Australia and Japan, and the answer was yes: relapse or withdrawal hit 63% on placebo, 39% on the low subcutaneous dose and 33% on the high dose, with a p value of 0.0007. Absolute risk reductions against placebo were 25 and 30 percentage points.
Privigen's role was upstream. Before randomisation, 207 IVIG-dependent patients were taken off immunoglobulin until they deteriorated, then restabilised on the intravenous product. On adjusted INCAT, 72.9% responded by week 13, 91% improved on at least one efficacy criterion, and the median time to first response was 3.7 weeks. A pooled analysis of PRIMA and PATH, published in 2019 and covering 235 patients, put the combined INCAT response at 71.5% with a median time to improvement of 4.3 weeks and 0.144 adverse drug reactions per infusion. The PATH trial itself is in The Lancet Neurology.
The haemolysis paper that audited the factory fix
Here's the unglamorous problem with concentrated antibody. Plasma contains antibodies against blood group A and B antigens — isoagglutinins — and a big enough dose of them will coat a patient's red cells and haemolyse them. Older Cohn fractionation stripped a lot of these out almost by accident. A 2015 comparison found the median anti-A titre in Sandoglobulin lots sat at 1:2 while Privigen lots ran at 1:16, because chromatography-based processes have no intrinsic capacity to remove isoagglutinins.
CSL Behring fixed it twice. From 2013 to 2015 it excluded donors with high anti-A titres, roughly 5% of the plasma supply, which trimmed the tail of high-titre lots without moving the median. From late 2015 it added immunoaffinity chromatography, passing the immunoglobulin solution through a resin carrying synthetic A and B trisaccharides so the isoagglutinins bind and leave. Median anti-A fell from 32 to 8, anti-B from 16 to 4.
Then came the part that matters: an audit of whether the fix worked in patients. Using the US hospital-based Premier Healthcare Database, a 2020 study in Transfusion tracked probable haemolytic anaemia across three manufacturing eras. Crude rates were 1.49 per 10,000 patient-days from 2008 to 2012 (38 cases among 9,439 patients), 1.01 during donor screening (20 cases among 7,710) and 0.14 after immunoaffinity chromatography (3 cases among 7,759). The adjusted incidence rate ratio for the final period was 0.10 — a reduction of about 90%. The authors' conclusion is blunt: haemolytic anaemia has become a rare event with this product. Read the hospital cohort study in Transfusion.
What pooled antibodies turned out to contain in 2023
Because IVIG is made from the plasma of thousands of donors, it passively inherits whatever those donors have been exposed to and vaccinated against. A 2023 paper in Clinical Infectious Diseases, from an academic group that ran the Francis Crick Institute's live-virus neutralisation assay, tested commercial products and the serum of patients receiving them. Median anti-spike antibody titres rose from 2,123 U/mL before infusion to 10,600 U/mL after, and neutralisation of both ancestral virus and Omicron BA.1 increased significantly.
The uncomfortable detail was variation. Batches of Intratect and Privigen showed significantly higher neutralisation against ancestral virus than other products, and against XBB the half-maximal effective concentration tended to be higher for Octagam and Privigen — the two that had otherwise neutralised earlier variants best. Some products varied batch to batch. The authors' practical suggestion was that batch-level neutralisation testing may be prudent before using a product therapeutically. The study is in Clinical Infectious Diseases.
Photo by Brett Jordan on Unsplash
What none of these five settles
Four of the five papers have manufacturer authors or manufacturer funding, and you should hold that in mind without treating it as misconduct — it's how plasma products get licensed. PRIMA was single-arm against a historical control. PATH was funded by CSL Behring. The stability paper and the haemolysis cohort are company work. Only the SARS-CoV-2 study is independent, and its finding on batch variation is the one no manufacturer would have chosen to publish.
No head-to-head trial has ever compared IVIG brands on clinical outcomes, so the differences that exist — stabiliser, pH, sodium content, isoagglutinin titre, sucrose or no sucrose — are read through labels and observational data rather than randomised comparisons.
And the boxed warning has not gone away. Four things the label is explicit about:
- Thrombosis can occur, including in people with no known risk factors, and the risk climbs with age, immobility, oestrogen use and cardiovascular disease.
- Renal dysfunction and acute renal failure can occur, which is why at-risk patients get the minimum dose at the minimum rate and are hydrated first.
- Haemolysis risk is highest for blood group AB, then A, and lowest for group O.
- Privigen is contraindicated in IgA-deficient patients with anti-IgA antibodies, and in hyperprolinaemia.
The CIDP indication is for adults. Use in children with CIDP is not established in the US label, and a hospital-based safety review of 28 paediatric CIDP patients given 486 Privigen administrations found no haemolytic anaemia, aseptic meningitis, acute renal failure, severe anaphylaxis or thromboembolic event, with two moderate anaphylactic reactions — 0.4% of administrations.
The arithmetic of a rare-disease label
Twenty-eight. That's the number of patients whose response rate carried the European CIDP authorisation, later reinforced by 207 people restabilised during PATH. Twenty-eight is small enough that a single atypical responder moves the percentage by several points, and it is also completely normal for a disease with an estimated incidence of up to two cases per 100,000 people per year in the United States.
The clinical consequence is a label that tells you to individualise rather than follow a protocol. Roughly 30% of untreated CIDP patients progress to wheelchair dependence, which sets the stakes, but the six-month cap on studied maintenance means the decision to continue is a judgement about that specific patient's deterioration off treatment, not a number in a table.
So the product that started all this by refusing to sit in a refrigerator ends up asking for something harder than cold storage: a clinician who knows what a patient looks like when the dose is right, and what they look like three weeks after it stops. The fridge, at least, is settled.
- Privigen
- immunoglobulin therapy
- CSL Behring
- plasma-derived therapies
- clinical trials

